{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:47:56Z","timestamp":1792813676900,"version":"4.5.0"},"reference-count":42,"publisher":"Informa UK Limited","issue":"6","funder":[{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2017,6,3]]},"DOI":"10.1080\/14740338.2017.1328052","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T02:51:00Z","timestamp":1494557460000},"page":"743-751","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension"],"prefix":"10.1080","volume":"16","author":[{"given":"Shirin","family":"Bruderer","sequence":"first","affiliation":[{"name":",","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Hurst","sequence":"additional","affiliation":[{"name":",","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Remenova","sequence":"additional","affiliation":[{"name":",","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Dingemanse","sequence":"additional","affiliation":[{"name":",","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,5,23]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2011.87"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040291"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.025"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.9739.1"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.124248"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707413"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0365-x"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2014.10.024"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.07.015"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.138305"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.169748"},{"key":"e_1_3_2_15_1","volume-title":"Uptravi USPI (selexipag, 200 mcg, 400 mcg, 600 mcg, 800, mcg, 1000 mcg, 1200 mcg, 1400 mcg, 1600 mcg) tablets. US Prescribing Information","year":"2015","unstructured":"Uptravi USPI (selexipag, 200 mcg, 400 mcg, 600 mcg, 800, mcg, 1000 mcg, 1200 mcg, 1400 mcg, 1600 mcg) tablets. US Prescribing Information. Actelion Pharmaceuticals Ltd; 2015 December."},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000367630"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12650"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.03.014"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12963"},{"key":"e_1_3_2_20_1","unstructured":"Krause A Machacek M Lott D et al. Population pharmacokinetics and pharmacodynamics of selexipag in patients with pulmonary arterial hypertension. CPT: Pharmacometrics & Systems Pharmacology Submitted 2016"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00137511"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503184"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-015-0117-4"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP202318"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S75565"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2004.01.003"},{"key":"e_1_3_2_27_1","volume-title":"Uptravi SPC Summary of product characteristics and highlights of prescribing information, selexipag","year":"2015","unstructured":"Uptravi SPC Summary of product characteristics and highlights of prescribing information, selexipag. Actelion Pharmaceuticals Ltd; 2015."},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602013340504"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199801293380501"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00463-7"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(03)00184-9"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-0193-0_45"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M003873200"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(15)61542-X"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(15)61558-3"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00094302"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e32833700fc"},{"key":"e_1_3_2_38_1","volume-title":"Treprostinil SPC Summary of product characteristics and highlights of prescribing information, Remodulin \u00ae","year":"2008","unstructured":"Treprostinil SPC Summary of product characteristics and highlights of prescribing information, Remodulin \u00ae. United Therapeutics Corp; 2008."},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199311000-00007"},{"key":"e_1_3_2_40_1","article-title":"0.5 mg powder and solvent for solution for infusion","author":"Flolan SPC Summary of product characteristics","year":"2015","unstructured":"Flolan SPC Summary of product characteristics. 0.5 mg powder and solvent for solution for infusion. GlaxoSmithKline. 2015.","journal-title":"GlaxoSmithKline"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.03.012"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.802682"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2013.09.003"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2164-4"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2017.1328052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T23:22:34Z","timestamp":1770420154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2017.1328052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,23]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6,3]]}},"alternative-id":["10.1080\/14740338.2017.1328052"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2017.1328052","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}